Abstract 1569P
Background
Recently, cancer organoid-based drug sensitivity tests have been studied to predict patient responses to anticancer drugs. This study proposes a multi-factor analysis method (cancer organoid-based diagnosis reactivity prediction, CODRP) that considers the cancer stage and cancer cell growth rate, which represent the severity of cancer patients, in the sensitivity test for gastric cancer patients.
Methods
Primary cells were isolated from surgical tissues from 143 gastric cancer (GC) patients and mixed with matrigel to make patient derived 3D cultured cells. Due to small number of patient’s cells, we used 384 pillar plate (MBD, Korea) for high throughput screening. 1.5ul spots dispensed on pillar and, the cells were stabilized in a culture medium optimized for GC cells for 3days and the drug response was observed for 7days. 3D cell morphology was scanned after calcein staining and cell viability was quantified using ATP assay. The primary characteristics of GC 3D cultured cells were confirmed by IHC. The drug responses were calculated by a sigmoidal dose response curve and compared to clinical case report form.
Results
Evaluation of drug response was established for various drugs in 143 patients and success rate was 71%. We analyzed drug response through CODRP analysis method using multi-factor (cell growth rate, TNM stage, AUC). In clinic, 56 patients were treated by oxaliplatin after surgery, the CODRP index about oxaliplatin compared with clinical response. Although the clinical recurrence rate was low due to the 1 year follow up, the early recurrence rate by CODRP analysis in the resistant group was 10%p higher than AUC analysis, while there was almost no difference in the sensitive group. When we analyze the 1-year recurrence-free survival rate in the CODRP model, the sensitive group showed 78% survival, while the resistant group showed 38.2% survival. Therefore, there was a significant difference in 1 year recurrence-free survival rate based on the CODRP model.
Conclusions
This study proposes a novel drug sensitivity prediction model using patient derived 3D cultured cells. In 56 gastric cancer patients, CODRP models based on the drug sensitivity AUC, growth rate, and cancer stage successfully predict clinical response of patient’s drug treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
MBD.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1645P - STAT3, ACTA2, and SPARC stromal markers predict response to Gemcitabine/Cisplatin/Nab-paclitaxel (GCN) in patients with advanced pancreatic adenocarcinoma (apdac)
Presenter: Himil Mahadevia
Session: Poster session 22
1646P - Genomic and prognostic differences in patients with different KRAS mutations in pancreatic cancer
Presenter: Chunwei Xu
Session: Poster session 22
1647P - Cancer-associated endocrine cell: A novel component of tumor microenvironment in pancreatic cancer
Presenter: Yuan Chen
Session: Poster session 22
1648P - Association between circulating tumor cell count and thrombosis in pancreatic cancer
Presenter: Monica Benavente
Session: Poster session 22
1649P - Comprehensive genomic profiling contributes to the prognosis of patients with advanced pancreatic cancer
Presenter: Eiichiro So
Session: Poster session 22
1650P - Identification of potential targets in pancreatic adenocarcinoma: The KRAS Wild-Type subset
Presenter: Daniel Acosta Eyzaguirre
Session: Poster session 22
1651P - Comparison of surgical outcome and prognostic factors between pancreaticobiliary and intestinal types of periampullary adenocarcinoma following pancreaticoduodenectomy
Presenter: Saad Anwar
Session: Poster session 22
1652P - Interaction between enhanced cytokine signalling and ferroptosis defence fuels obesity-associated pancreatic ductal adenocarcinoma oncogenesis
Presenter: Rishat Ruzi
Session: Poster session 22
1653P - The activated thermogenesis of intra-pancreatic fat fuels the progression of pancreatic cancer
Presenter: Xi'n'peng Yin
Session: Poster session 22
1654P - Circulating tumor cells (CTCs) as prognostic factor for pancreatic cancer: Updated of a prospective study
Presenter: Natalia Gutierrez Alonso
Session: Poster session 22